NDAINTRAVENOUSINJECTABLE, LIPOSOMAL
Approved
Aug 2012
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
2/8 — Basic
Drug data last refreshed 3h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MARQIBO KIT is a liposomal formulation of vincristine sulfate, a vinca alkaloid microtubule inhibitor approved in 2012 for intravenous administration. It is indicated for hematologic malignancies, primarily acute lymphoblastic leukemia (ALL) and other blood cancers. The liposomal encapsulation improves pharmacokinetics and reduces neurotoxicity compared to conventional vincristine.
Peak
Product is in peak commercial phase with moderate competitive pressure (30), indicating stable revenue but limited growth runway.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (5)
Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia
Started Jan 2021
0Allogeneic Hematopoietic Stem Cell Transplantation RecipientBlasts 5 Percent or More of Bone Marrow Nucleated CellsBlasts 5 Percent or More of Peripheral Blood White Cells+5 more
Phase III Study of Vincristine Sulfate Liposome For Injection In Adults With Naïve Acute Lymphoblastic Leukemia
Started Jun 2013
480 enrolled
Adult Acute Lymphoblastic Leukemia
Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction
Started Feb 2005
7 enrolled
Malignant Melanoma
Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Started Jul 2002
36 enrolled
Acute Lymphoblastic Leukemia
Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL
Started Sep 2001
22 enrolled
Non-Hodgkin's LymphomaDiffuse Large B-cell LymphomaMantle Cell Lymphoma
Worked on MARQIBO KIT at Acrotech Biopharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.